A systematic review of experimental therapies for metastatic castration-resistant prostate cancer (mCRPC) found that while new immune cell approaches show potential, lasting benefits are still uncommon. The review looked at treatments like PSMA-directed CAR-T cells and other engineered immune cells, including those from stem cells and natural killer cells.
These next-generation therapies are designed to overcome current limitations, such as the need for personalized manufacturing and poor persistence in the body. They offer off-the-shelf availability and better resistance to the tumor's hostile environment. However, the tumor's ability to suppress the immune system, along with antigen heterogeneity and poor T-cell fitness, remain major hurdles.
No safety data were reported in this review. The findings are based on early-stage research, and the evidence is not strong enough to change current practice. The review serves as a strategic blueprint for future development, but patients should not expect these treatments to be available soon.
For now, standard treatments remain the main option. Anyone interested in these experimental therapies should discuss clinical trials with their doctor.
